GlassScriptPhysician profile
Christopher J Dipaolo
NPI 1134111891
$3,177.57
in general payments reported to CMS, 2019-2025
24 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $371 · 2021: $228 · 2022: $431 · 2023: $295 · 2024: $440 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,700.83 | 2019-2025 | Resonate El Icd Vr, Lux-Dx Insertable Cardiac Monitor, Avvigo Guidance System |
| Abbott Laboratories | $216.34 | 2025 | Aveir, Gallant |
| Biosense Webster, INC. | $168.72 | 2022-2024 | Carto 3 |
| Janssen Pharmaceuticals, INC | $161.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $112.25 | 2019-2025 | |
| Shockwave Medical, INC | $109.29 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $99.20 | 2022-2024 | Concertotm |
| Biotronik INC. | $92.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $63.30 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.03 | 2024-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.08 | 2019-2022 | |
| Philips North America LLC | $44.20 | 2019 | |
| Merck Sharp & Dohme LLC | $40.25 | 2021-2022 | |
| Edwards Lifesciences Corporation | $35.61 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.71 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $27.62 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.41 | 2025 | Amvuttra |
| Abiomed | $22.79 | 2023 | Impella |
| Cook Medical LLC | $21.82 | 2023 | Zenith |
| Elutia, INC. | $19.76 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $18.12 | 2024 | Arcalyst |
| Pfizer INC. | $16.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.93 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.55 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dipaolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.